Value proposition

Redefining Synthetic Lethality beyond HRD

Tessellate BIO discovers and develops novel precision oncology medicines with the mission to turn cancer patients into cancer survivors.

A private preclinical stage biotechnology company, Tessellate BIO is redefining Synthetic Lethality by developing drugs that target unexplored or difficult to drug pathways beyond HRD.

Headquartered in the Netherlands and with research labs at the Stevenage Bioscience Catalyst, UK, Tessellate BIO is supported by top-tier life science investors BioGeneration Ventures (BGV) and Forbion.

drug discovery, precision oncology, and biotechnology